George Z Rassidakis Selected Research

Neoplasms (Cancer)

10/2019	STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer.
7/2019	AP-1 Transcription Factors as Regulators of Immune Responses in Cancer.
1/2019	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
10/2018	Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
1/2018	Expression Analysis of miR-29b in Malignant and Benign Breast Tumors: A Promising Prognostic Biomarker for Invasive Ductal Carcinoma With a Possible Histotype-Related Expression Status.
1/2018	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
1/2018	Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm.
11/2016	mTOR downstream effectors, 4EBP1 and eIF4E, are overexpressed and associated with HPV status in precancerous lesions and carcinomas of the uterine cervix.
1/2015	Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role.
12/2014	SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

George Z Rassidakis Research Topics

Disease

50	Neoplasms (Cancer) 10/2019 - 02/2002
31	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 07/2023 - 09/2002
21	Lymphoma (Lymphomas) 07/2023 - 01/2002
12	Hodgkin Disease (Hodgkin's Disease) 01/2021 - 02/2002
9	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 08/2011 - 01/2003
6	Breast Neoplasms (Breast Cancer) 01/2020 - 05/2002
6	Carcinogenesis 03/2016 - 03/2006
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 08/2011 - 01/2003
3	T-Cell Lymphoma (Lymphoma, T Cell) 07/2023 - 09/2002
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 03/2020 - 04/2005
3	Carcinoma (Carcinomatosis) 10/2019 - 06/2005
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2019 - 03/2007
3	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019 - 09/2004
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2018 - 08/2006
2	Adenocarcinoma 01/2018 - 09/2006
2	Papillary Thyroid Cancer 12/2014 - 12/2011
2	Thyroid Neoplasms (Thyroid Cancer) 12/2014 - 12/2011
2	Multiple Myeloma 08/2011 - 09/2004
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 02/2008 - 06/2003
2	Lymphomatoid Papulosis 03/2007 - 08/2004
2	Residual Neoplasm 02/2002 - 02/2002
1	Bites and Stings (Sting) 02/2022
1	Histiocytic Sarcoma 03/2020
1	Ductal Carcinoma 01/2018
1	Juvenile Myelomonocytic Leukemia 01/2018
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 11/2016
1	Squamous Intraepithelial Lesions 11/2016
1	Papillomavirus Infections 11/2016
1	Hepatocellular Carcinoma (Hepatoma) 03/2016
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2015
1	Carcinoid Tumor (Carcinoid) 01/2015

Drug/Important Bio-Agent (IBA)

26	Anaplastic Lymphoma KinaseIBA 06/2022 - 09/2002
24	Proteins (Proteins, Gene)FDA Link 07/2023 - 02/2002
7	Phosphotransferases (Kinase)IBA 06/2022 - 08/2004
7	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 03/2002
6	Carrier Proteins (Binding Protein)IBA 11/2016 - 03/2003
6	TOR Serine-Threonine KinasesIBA 11/2016 - 07/2006
6	ParaffinIBA 08/2005 - 02/2002
5	Rituximab (Mabthera)FDA Link 01/2019 - 02/2002
5	Pyridinolcarbamate (P23)IBA 11/2014 - 06/2003
4	Biomarkers (Surrogate Marker)IBA 02/2022 - 03/2017
4	Eukaryotic Initiation Factor-4EIBA 11/2016 - 12/2006
4	Cyclin D1IBA 10/2009 - 01/2003
3	Messenger RNA (mRNA)IBA 02/2022 - 10/2005
3	Vincristine (Oncovin)FDA LinkGeneric 01/2019 - 03/2002
3	Cytarabine (Cytosar-U)FDA LinkGeneric 10/2018 - 03/2009
3	Dexamethasone (Maxidex)FDA LinkGeneric 03/2009 - 02/2002
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 02/2008 - 10/2005
3	Formaldehyde (Formol)FDA Link 08/2005 - 09/2003
3	Dacarbazine (DIC)FDA LinkGeneric 06/2003 - 03/2002
3	Vinblastine (Vinblastine Sulfate)FDA Link 06/2003 - 03/2002
3	Bleomycin (Blenoxane)FDA LinkGeneric 06/2003 - 03/2002
3	Mitoxantrone (Novantrone)FDA LinkGeneric 03/2002 - 02/2002
2	nutlin 3IBA 07/2023 - 06/2007
2	SAM Domain and HD Domain-Containing Protein 1IBA 01/2021 - 10/2018
2	B7-H1 AntigenIBA 01/2020 - 10/2019
2	Estrogen ReceptorsIBA 01/2020 - 01/2018
2	Transcription Factors (Transcription Factor)IBA 07/2019 - 06/2005
2	Prednisone (Sone)FDA LinkGeneric 01/2019 - 03/2002
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 03/2009
2	LigandsIBA 01/2019 - 01/2018
2	Monoclonal AntibodiesIBA 01/2018 - 08/2004
2	70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA 11/2010 - 07/2006
2	Methotrexate (Mexate)FDA LinkGeneric 10/2009 - 03/2009
2	Indicators and Reagents (Reagents)IBA 07/2007 - 06/2003
2	CytokinesIBA 07/2007 - 08/2005
2	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2007 - 08/2004
2	Ribosomal Protein S6IBA 12/2006 - 07/2006
2	PAX5 Transcription FactorIBA 08/2006 - 04/2004
2	Caspase 3 (Caspase-3)IBA 07/2006 - 01/2004
2	Tissue Inhibitor of Metalloproteinase-1IBA 11/2005 - 06/2004
2	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 08/2005 - 07/2004
2	Interleukin-10 (Interleukin 10)IBA 10/2004 - 06/2003
2	fludarabineIBA 02/2002 - 02/2002
1	ProteomeIBA 07/2023
1	InterferonsIBA 02/2022
1	trametinibIBA 03/2020
1	dabrafenibIBA 03/2020
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 07/2019
1	GTPase-Activating Proteins (GTPase-Activating Protein)IBA 01/2018
1	mouse MIRN29 microRNAIBA 01/2018
1	MicroRNAs (MicroRNA)IBA 01/2018
1	Immune Checkpoint InhibitorsIBA 01/2018
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 03/2016
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2015
1	somatostatin receptor 2IBA 01/2015
1	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2015
1	Dopamine Agonists (Dopamine Agonist)IBA 01/2015
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2015
1	somatostatin receptor type 1IBA 01/2015
1	Mechanistic Target of Rapamycin Complex 2IBA 12/2014
1	JNK Mitogen-Activated Protein KinasesIBA 03/2014

Therapy/Procedure

8	Therapeutics 07/2019 - 11/2003
5	Investigational Therapies (Experimental Therapy) 10/2005 - 06/2003
3	Immunotherapy 07/2019 - 01/2018
2	Drug Therapy (Chemotherapy) 07/2006 - 05/2004
2	Splenectomy 04/2006 - 01/2002
2	Radiotherapy 10/2004 - 03/2002
1	Breast Implants (Breast Implant) 07/2023
1	Consolidation Chemotherapy 10/2018